Imfinzi and Imjudo with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
Approval based on POSEIDON Phase III trial results, which showed significant survival benefit with a limited course of Imjudo added to Imfinzi and chemotherapy.AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC). The approval by the Food and Drug Administration (FDA) was based on the results from the POSEIDON Phase III trial